Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $16.60.

Several analysts recently issued reports on AMRX shares. Barclays upped their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Weiss Ratings cut Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Finally, UBS Group increased their price objective on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Rubric Capital Management LP grew its holdings in Amneal Pharmaceuticals by 5.3% during the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after purchasing an additional 624,609 shares during the period. Dimensional Fund Advisors LP raised its stake in Amneal Pharmaceuticals by 1.5% in the first quarter. Dimensional Fund Advisors LP now owns 5,690,586 shares of the company’s stock valued at $70,723,000 after buying an additional 81,546 shares during the period. Morgan Stanley raised its stake in Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after buying an additional 1,315,018 shares during the period. Nantahala Capital Management LLC raised its stake in Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after buying an additional 558,877 shares during the period. Finally, State Street Corp lifted its position in shares of Amneal Pharmaceuticals by 3.4% in the fourth quarter. State Street Corp now owns 4,110,410 shares of the company’s stock valued at $51,791,000 after buying an additional 136,662 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Trading Down 1.1%

Amneal Pharmaceuticals stock opened at $17.85 on Monday. The company has a market cap of $5.69 billion, a P/E ratio of 46.97 and a beta of 1.26. Amneal Pharmaceuticals has a 1-year low of $7.66 and a 1-year high of $18.39. The company has a fifty day simple moving average of $15.05 and a 200 day simple moving average of $13.89.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. The firm had revenue of $722.52 million for the quarter. On average, equities research analysts forecast that Amneal Pharmaceuticals will post 0.92 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.